Page 20 - digital-envision05-2021
P. 20

A Biological Bandage for

                                                   OCULAR SURFACE

                                       DISEASES












                                                                  Making Contact

                                                               By Shirley Ha, BSc. (Hons), OD, FCOVD
                                  early half of all patients visiting eye clinics have a complaint that could be a sign of
                                  aqueous-deficient and/or evaporative dry eye disease (ADE/EDE). According to the
                                  2017 TFOS DEW II report, the prominent characteristic in this multifactorial ocular
                                  surface disease is chronic inflammation  having direct and harmful effects at the cellular
                                                                     1
                       Nlevel (epitheliopathy) and at the nerve level (loss of corneal nerves). The consequent
                         mobilization of both the innate and adaptive immune cells drives dry eye disease (DED) into a
                         vicious circle of self-perpetuating inflammation. There is also an increased risk of DED associated
                         with certain medical conditions that target the immune system, such as rheumatoid arthritis,
                         Lupus, Sjögren’s syndrome and Graves’ disease.
                                      Current treatment protocols (artificial  be used as an adjunct to dry eye
                                      tears, dietary supplementation, thermal  strategies (punctal occlusion, autologous
                                      massage therapy, secretagogues, intense  serum, tarsorrhaphy, etc.) and systemic
                                      pulsed light therapy, scleral contact lenses,  immunotherapy.
                                      medications to suppress or interrupt the
                                      inflammatory cascade) are often recalcitrant    Since 1995, the AM has been shown to be
                                      in some complicated, immune-mediated    effective in treating many ocular surface
                                      DED, despite compliant use. Hence, the   and  other  inflammatory  disorders,
                                      evolving management of these cases    including, but not limited to, DED,
                                      should also include the PROKERA®’s line   infectious keratitis, corneal ulcers, chemical
                                      of cryopreserved amniotic membranes   burns, bullous keratopathy, degenerative
                                      (CAM) from Bio-Tissue, Miami, FL, or the     corneal diseases and corneal nerve
                                      BioDOPTIX® dehydrated amniotic membrane   damage from diabetes or exposure
                                      (DAM) from Labtician Ophthalmics,   keratitis. It is donated by and harvested
                                      Oakville, ON, as a pre-emptive, rather than  from  consenting,  healthy  mothers  who
                                      last resort, therapeutic option. Both can    have had C-sections to regulated tissue


      18  /  MAY - JUNE 2021   /   www.ENVISIONMAGAZINE.ca  /
   15   16   17   18   19   20   21   22   23   24   25